ArticleThe Prostate2026
Cystoscopic ICG-Guided Sentinel Lymph Node Dissection in Robotic Radical Prostatectomy: A Prospective Study.
Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cystoscopic ICG-Guided Sentinel Lymph Node Dissection in Robotic Radical Prostatectomy: A Prospective Study.The Prostate · 2026Article
- Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the diagnostic accuracy, procedural feasibility, and clinical outcomes of a novel cystoscopic-guided indocyanine green (ICG) injection technique followed by fluorescence-guided sentinel lymph node dissection (SLND) during robotic-assisted radical prostatectomy (RaRP), hereafter referred to as CysICG-SLND.
methodsWe prospectively enrolled patients with clinically localized prostate cancer (cT1-cT3, cN0) scheduled for RaRP between November 2019 and May 2020. Each patient received cystoscopic-guided intraprostatic injections of ICG, with injection volumes tailored according to prostate size. SLND was performed using the da Vinci Xi Surgical System equipped with near-infrared imaging and followed by a routine extended pelvic lymph node dissection (ePLND). Diagnostic accuracy, procedural complications, and medium-term oncological outcomes were analyzed.
resultsA total of 34 patients were included (risk category: low = 2, intermediate = 11, high = 21). Cystoscopic ICG injection was technically successful in all cases. The overall fluorescence detection rate was 97.1%, with excellent per-patient sensitivity (100%) and negative predictive value (NPV) (100%) across all patients. However, per-node diagnostic performance was moderate (sensitivity 66.7%, specificity 47.8%). Notably, in the high-risk group, per-node performance was modest, with sensitivity, specificity, positive predictive value (PPV), and NPV of 66.7%, 55.2%, 20.5%, and 90.7%, respectively. No metastatic nodes were identified in low-risk and intermediate-risk groups, demonstrating a reliable 100% NPV in these subpopulations. High-risk patients had significantly higher biochemical recurrence (BCR) rates compared to lower-risk groups (p = 0.017). There were no allergic reactions or postoperative complications attributable to ICG.
conclusionsCysICG-SLND is a feasible, accurate approach for nodal staging in prostate cancer, particularly beneficial in low- to intermediate-risk groups, achieving excellent sensitivity and NPV. Although diagnostic performance is limited in high-risk patients, high per-patient accuracy still supports clinical utility. Larger prospective studies are warranted to validate these results and further elucidate the technique's clinical role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.